US Pharma MarketingThe drugmaker is leaning on a better side effect profile compared to drugs from J&J, Pfizer and Regeneron as it pushes etentamig toward FDA submission.
Trailing rivals, AbbVie scores win with dual-acting myeloma drug
The drugmaker is leaning on a better side effect profile compared to drugs from J&J, Pfizer and Regeneron as it pushes etentamig toward FDA submission.
Source: BioPharma Dive